Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. by Mallewa, J et al.
www.thelancet.com/hiv   Vol 5   May 2018 e231
Articles
Effect of ready-to-use supplementary food on mortality 
in severely immunocompromised HIV-infected individuals 
in Africa initiating antiretroviral therapy (REALITY): 
an open-label, parallel-group, randomised controlled trial
Jane Mallewa, Alexander J Szubert, Peter Mugyenyi, Ennie Chidziva, Margaret J Thomason, Priscilla Chepkorir, George Abongomera, Keith Baleeta, 
Anthony Etyang, Colin Warambwa, Betty Melly, Shepherd Mudzingwa, Christine Kelly, Clara Agutu, Helen Wilkes, Sanele Nkomani, Victor Musiime, 
Abbas Lugemwa, Sarah L Pett, Mutsa Bwakura-Dangarembizi, Andrew J Prendergast, Diana M Gibb*, A Sarah Walker*, James A Berkley* on behalf of 
the REALITY trial team
Summary
Background In sub-Saharan Africa, severely immunocompromised HIV-infected individuals have a high risk of mortality 
during the first few months after starting antiretroviral therapy (ART). We hypothesise that universally providing ready-
to-use supplementary food (RUSF) would increase early weight gain, thereby reducing early mortality compared with 
current guidelines recommending ready-to-use therapeutic food (RUTF) for severely malnourished individuals only.
Methods We did a 2 × 2 × 2 factorial, open-label, parallel-group trial at inpatient and outpatient facilities in eight urban 
or periurban regional hospitals in Kenya, Malawi, Uganda, and Zimbabwe. Eligible participants were ART-naive 
adults and children aged at least 5 years with confirmed HIV infection and a CD4 cell count of fewer than 100 cells 
per µL, who were initiating ART at the facilities. We randomly assigned participants (1:1) to initiate ART either with 
(RUSF) or without (no-RUSF) 12 weeks’ of peanut-based RUSF containing 1000 kcal per day and micronutrients, 
given as two 92 g packets per day for adults and one packet (500 kcal per day) for children aged 5–12 years, regardless 
of nutritional status. In both groups, individuals received supplementation with RUTF only when severely 
malnourished (ie, body-mass index [BMI] <16–18 kg/m² or BMI-for-age Z scores <–3 for children). We did the 
randomisation with computer-generated, sequentially numbered tables with different block sizes incorporated within 
an online database. Randomisation was stratified by centre, age, and two other factorial randomisations, to 12 week 
adjunctive raltegravir and enhanced anti-infection prophylaxis (reported elsewhere). Clinic visits were scheduled at 
weeks 2, 4, 8, 12, 18, 24, 36, and 48, and included nurse assessment of vital status and symptoms and dispensing of 
all medication including ART and RUSF. The primary outcome was mortality at week 24, analysed by intention to 
treat. Secondary outcomes included absolute changes in weight, BMI, and mid-upper-arm circumference (MUAC). 
Safety was analysed in all randomly assigned participants. Follow-up was 48 weeks. This trial is registered with 
ClinicalTrials.gov (NCT01825031) and the ISRCTN registry (43622374).
Findings Between June 18, 2013, and April 10, 2015, we randomly assigned 1805 participants to treatment: 897 to 
RUSF and 908 to no-RUSF. 56 (3%) were lost-to-follow-up. 96 (10·9%, 95% CI 9·0–13·1) participants allocated to 
RUSF and 92 (10·3%, 8·5–12·5) to no-RUSF died within 24 weeks (hazard ratio 1·05, 95% CI 0·79–1·40; log-rank 
p=0·75), with no evidence of interaction with the other randomisations (both p>0·7). Through 48 weeks, adults and 
adolescents aged 13 years and older in the RUSF group had significantly greater gains in weight, BMI, and MUAC 
than the no-RUSF group (p=0·004, 0·004, and 0·03, respectively). The most common type of serious adverse event 
was specific infections, occurring in 90 (10%) of 897 participants assigned RUSF and 87 (10%) of 908 assigned 
no-RUSF. By week 48, 205 participants had serious adverse events in both groups (p=0·81), and 181 had grade 4 adverse 
events in the RUSF group compared with 172 in the non-RUSF group (p=0·45).
Interpretation In severely immunocompromised HIV-infected individuals, providing RUSF universally at ART 
initiation, compared with providing RUTF to severely malnourished individuals only, improved short-term weight 
gain but not mortality. A change in policy to provide nutritional supplementation to all severely immunocompromised 
HIV-infected individuals starting ART is therefore not warranted at present.
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Introduction
WHO guidelines recommend universal antiretroviral 
therapy (ART) for HIV-infected individuals regardless of 
their CD4 cell counts.1 However, 20–25% of HIV-infected 
individuals in sub-Saharan Africa still present for care 
with severe immunosuppression (ie, CD4 cell count 
<100 cells per µL),2 of whom around 10% die within 
3 months of ART initiation.3 Early mortality is higher in 
adults and children with low CD4 cell counts or low 
body-mass index (BMI), even if these levels are above 
those indicating severe malnutrition.4
Macronutrient and micronutrient undernutrition is 
common in HIV-infected individuals and might be a result 
of anorexia, swallowing difficulties, food insecurity, 
frequent illness, intestinal dysfunction, and the increased 
nutrient demands posed by immune activation and 
opportunistic infections.5 Food insecurity has also been 
associated with poor recovery of CD4 cell counts, reduced 
adherence to ART, and low retention in care.5,6 Energy 
requirements are increased by about 10% in HIV-infected 
individuals who are not sick, and by 20–50% during 
symptomatic disease and initial recovery.7 Many patients 
report acute hunger after starting ART, but might be 
unable to increase their calorie intake.8 However, precise 
macronutrient and micronutrient requirements for 
individuals initiating ART at different stages of HIV 
disease have not been defined.
WHO and UNAIDS recommendations for people living 
with HIV focus on nutritional assessment, counselling 
and support to provide a balanced diet with adequate 
energy, and food supplementation for severely 
malnourished individuals, or for individuals in food-
insecure areas.1,9 Thus, typically, national guidelines 
currently recommend screening individuals with their 
BMI and providing nutritional supplementation 
selectively to individuals defined as severely malnourished. 
In sub-Saharan Africa, national guidelines vary widely in 
their recommendations on provision of ready-to-use lipid-
based nutritional supplements;10 however, they are 
increasingly being given within HIV programmes in the 
region.11
Lipid-based supplementary foods have been 
highlighted as a key potential intervention to reduce 
mortality in severely immunocompromised HIV-infected 
individuals by improving both nutritional status and 
antiretroviral drug absorption.12 There are several 
mechanisms by which such supplementary foods could 
have beneficial effects on mortality. For example, 
improved nutrition could have direct effects on mucosal 
barriers and immune function, reducing inflammation 
and thereby reducing the nuclear factor κ-light-chain-
enhancer of activated B cell-induced enhancement of 
viral replication. Alternatively, improved strength and 
wellbeing and less hunger could improve ART adherence, 
or enhanced nutritional intake could improve drug 
absorption and metabolism directly. However, lipid-
based supplementary foods are more expensive than 
other forms of macronutrient supplementation or 
nutritional counselling alone. Meta-analyses of trials of 
food supplementation or macronutrient supplements 
across a range of HIV-disease stages and stages of 
undernutrition have reported inconclusive evidence on 
mortality, virological, immunological, and functional 
outcomes.13,14
We therefore did the Reduction of EArly mortaLITY 
(REALITY) trial in four sub-Saharan African countries to 
investigate whether universally providing ready-to-use 
supplementary food (RUSF) to improve nutritional 
status after ART initiation reduced early mortality in 
severely immunocompromised HIV-infected adults and 
Research in context
Evidence before this study
We searched published articles in PubMed without date or 
language restriction containing the terms (“HIV”[MeSH Terms] 
OR “HIV”[All Fields]) AND ((OR (“nutritional”[All Fields]) OR 
“nutritional status”[All Fields] OR “nutrition”[All Fields] 
OR nutritional[All Fields] OR feeding[All Fields]) AND 
((“dietary supplements”[MeSH Terms] OR (“dietary”[All Fields] 
AND “supplements”[All Fields]) OR “dietary supplements”[All 
Fields] OR “supplement”[All Fields]) OR “supplementation”[All 
Fields])) AND (“clinical trials as topic”[MeSH Terms] OR 
“trial”[All Fields]). Previous studies have included severely 
malnourished and non-severely malnourished HIV-infected 
individuals, predominantly in the absence of severe 
immunosuppression. The findings showed that lipid-based 
nutritional supplementation at ART initiation was associated 
with weight gain, but provided no evidence of a reduction in 
mortality. A systematic review concluded that the effect of 
nutritional supplementation on mortality, morbidity, and 
disease outcomes was uncertain. No nutritional trials reported 
targeting individuals who were at high risk of mortality after 
starting ART because of severe immunosuppression.
Added value of this study
In our randomised controlled trial, the group universally 
receiving RUSF gained more weight in the short term than the 
group who received supplementation only if they were severely 
malnourished according to current guidelines. However, there 
was no significant difference in deaths, adverse events, viral 
load suppression, or CD4 cell counts.
Implications of all the available evidence
HIV-infected individuals with severe malnutrition should 
continue to be identified and treated, but a change in policy to 
provide lipid-based nutritional supplements universally to all 
severely immunocompromised HIV-infected individuals 
starting ART is not warranted.
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children aged at least 5 years. We report the effect of 
universal provision of nutritional supplementation on 
mortality, disease progression, and anthropometry 
among these severely immunocompromised individuals 
at ART initiation compared with the current standard of 
care of providing nutritional intervention only to 
individuals identified as severely malnourished.
Methods
Study design and participants
We did a 2 × 2 × 2 factorial, open-label, parallel-group trial at 
inpatient and outpatient facilities in eight urban or 
periurban regional hospitals in Kenya, Malawi, Uganda, 
and Zimbabwe. The trial was approved by ethics 
committees in Kenya (Moi University Institutional 
Research and Ethics Committee and the Kenya Medical 
Research Institute Ethics Review Committee), Malawi 
(College of Medicine Research Ethics Committee), Uganda 
(Joint Clinical Research Centre Institutional Review Board 
and the Uganda National Council for Science and 
Technology), the UK (University College London Ethics 
Committee), the USA (Indiana University Institutional 
Review Board), and Zimbabwe (Joint Parirenyatwa 
Hospital and College of Health Sciences Research Ethics 
Committee and the Medical Research Council of 
Zimbabwe).
We consecutively approached adults and children aged 
at least 5 years with a diagnosis of HIV infection 
identified through national screening programmes, who 
were not on ART and reported no previous ART, and 
were initiating ART at one of the facilities, with CD4 
counts of fewer than 100 cells per µL, for screening. In 
centres where CD4 cell counts were not routinely done at 
diagnosis, patients with a new diagnosis of HIV were 
approached consecutively for CD4 testing and study 
screening. Exclusion criteria were pregnancy or 
breastfeeding, use of single-dose nevirapine to 
prevent mother-to-child-transmission of HIV, and any 
contraindications to nutritional supplementation or trial 
drugs. Adults and children’s guardians gave written 
informed consent; older children gave additional assent 
following national guidelines.
Randomisation and masking
We randomly assigned participants (1:1) to initiate ART 
with or without universal provision of 12 weeks of peanut-
based RUSF providing 1000 kcal/day and micronutrients 
as two 92 g foil packets daily (children aged 5–12 years 
received one 92 g foil packet of RUSF daily, providing 
500 kcal per day; appendix p 2). This was designed to 
replicate the way that supplementary foods are typically 
used in practice and in line with recent trials,15–17 rather 
than individually targeting estimates of individuals’ 
energy gap. In both groups, those identified as 
malnourished according to national criteria (generally 
BMI <16–18 kg/m², or for children, measures equivalent 
to BMI-for-age Z scores <–3; appendix pp 2–3) were 
referred to the local nutrition programme for ready-to-use 
therapeutic food (RUTF) whenever it was available, as 
normally done in routine care. RUTF has similar 
composition to RUSF, but might be prescribed 
in different quantities. If RUTF was not available, 
malnourished participants randomly assigned to RUSF 
received that instead; those assigned to no-RUSF did not 
receive any supplementation in accordance with local 
clinical practice. Therefore, the randomisation compared 
universal provision of nutritional supplementation with 
RUSF or RUTF (RUSF) with the selective provision of 
RUTF only for malnourished individuals (no-RUSF).
We also tested two other separate interventions using a 
factorial 2 × 2 × 2 design; participants were also randomly 
assigned (1:1) to 12 weeks of ART intensification with 
raltegravir versus no added raltegravir, and to enhanced 
infective prophylaxis18 versus standard co-trimoxazole 
prophylaxis (appendix pp 2–3). These other randomised 
interventions are reported separately. Randomisation was 
stratified by centre, age (up to 12 years or 13 years and 
older), and the other factorial randomisations. A computer-
generated sequential randomisation list with permuted 
blocks of different sizes was prepared by the trial statistician 
and incorporated securely into the online trial database. 
The list was concealed until allocation, after eligibility was 
confirmed by local centre staff who then did the 
randomisation. Nurses and physicians assessing outcomes 
were not masked to group assignment, but information on 
the randomised allocation was not available to staff assaying 
laboratory tests. 
Procedures
All participants initiated ART with two nucleoside-reverse-
transcriptase-inhibitors and one non-nucleoside-reverse-
transcriptase-inhibitor. RUSF was purchased from Valid 
International. Clinic visits were scheduled at weeks 2, 4, 8, 
12, 18, 24, 36, and 48, and included nurse assessment of 
vital status and symptoms by use of a standardised 
checklist, self-reported adherence assessment (including 
any missed doses in the previous 4 weeks) by participants 
or children’s carers, and dispensing of all medication 
including ART and RUSF. Standard adherence support 
was provided following local clinic practice. Food 
insecurity was assessed by self-report at baseline (by 
asking whether there was enough food to provide everyone 
in the household with regular meals). Body composition 
and basal metabolic rate were assessed at these visits by 
bioimpedance analysis with a Tanita BC-420MA machine. 
At enrolment and weeks 4, 12, and 48, grip strength was 
measured with a Takei 5401 Hand Grip Dynamometer. In 
Zimbabwe only, two body circumferences and four 
skinfold thicknesses were measured at enrolment and 
weeks 12 and 48 (appendix p 4). At enrolment and weeks 4, 
12, 24, 36, and 48, history was taken and examination was 
done by physicians; haematology, biochemistry (weeks 0, 
4 and 48 only), and CD4 cell counts were done; and plasma 
was stored for retrospective measurement of HIV viral 
See Online for appendix
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load (results were not available in real time). Toxicity 
substitution or second-line treatment switches were at 
physicians’ discretion, following WHO guidelines.19 
Participants exited the trial after 48 weeks.
Outcomes
The primary outcome was all-cause mortality to 24 weeks. 
Secondary outcomes assessed at 48 weeks were all-cause 
mortality; serious adverse events, grade 4 adverse events, 
and adverse events leading to modification of ART or 
trial drugs;20,21 absolute changes in weight, mean upper-
arm circumference (MUAC), and BMI; viral load; CD4 
cell counts; incidence of new diagnoses of tuberculosis, 
cryptococcal disease, candidiasis, or severe bacterial 
infections; admissions to hospital; self-reported 
adherence (reporting any missed doses in the previous 
4 weeks) to RUSF and ART, and acceptability of RUSF. 
Secondary clinical endpoints, cause of death and trial-
drug relatedness were adjudicated against protocol-
defined criteria by an endpoint review committee (most 
of whom were independent members), masked to trial 
interventions received, using available clinical or 
laboratory data; this committee also adjudicated whether 
events were newly occurring during the trial or had been 
pre-existing at baseline. We assessed mortality at 
12 weeks in an exploratory analysis. Loss to follow-up 
was defined as no clinic attendance for more than 
90 days. 
Statistical analysis
We calculated that 1800 adults and children would 
provide more than 80% power to detect a 50% relative 
reduction in 24 week all-cause mortality from 7% to 3·5% 
(two-sided α=0·05), allowing for a 5% loss to follow-up 
and a single inflation factor to allow for the factorial 
design. The effect size was based on achieving a clinically 
meaningful absolute reduction in mortality for at least 
one of the three randomisations.
Interim data were reviewed by an independent data 
monitoring committee (in three annual meetings) with 
the Haybittle-Peto criterion (p<0·001). Randomised 
groups were compared following intention to treat with 
log-rank tests for time-to-event outcomes (including 
mortality and time-to-new-disease events), Fisher’s exact 
tests for binary outcomes, Poisson models for counts of 
admissions to hospital, and generalised estimating 
equations with independent working correlation for 
global tests of repeated measures (normal distribution for 
BMI, weight, CD4 cell counts, and other continuous 
outcomes; and logistic distribution for self-reported 
adherence and suppression of viral load). Primary 
analyses were stratified by the randomisation stratification 
factors (including stratification factors and scheduled 
visit week as categorical independent variables in the 
generalised estimating equations). Prespecified subgroup 
analyses were done by the other factorial randomisations, 
age, site, country, baseline CD4 cell count, type of ART, 
and BMI (appendix pp 4–5). Where data were missing, 
denominators are given and analysis was based on 
complete- lated based on days prescribed, but excluding 
the time after participants or physicians reported that it 
had been permanently discontinued. This outcome also 
excluded any time participants reported they had not 
taken it completely, and occurring any time after 
prescriptions would have finished (eg, due to a late return 
to clinic). This calculation did not incorporate any 
adjustment for self-reported non-adherence. We analysed 
the data with Stata version 15.1. This trial is registered 
with ClinicalTrials.gov (NCT01825031) and the ISRCTN 
registry (43622374).
Figure 1: Trial profile
ART=antiretroviral therapy. RUSF=ready-to-use supplementary food. RUTF=ready-to-use therapeutic food. 
*Reasons were not mutually exclusive, therefore total is more than the number of patients not randomly assigned 
treatment. †Considered too unwell (one patient), not able to comply with trial schedule (one patient), and no 
further details (one patient). ‡Ten patients ineligible after randomisation (four previously received ART, one RUSF 
contraindicated [milk allergy]), one 3 months pregnant, one had CD4 count ≥100 cells per µL at screening [38 cells 
per µL at enrolment], one randomly assigned 7 weeks after screening, two incorrect consent [one aged 14 years 
gave assent but without caregiver consent at enrolment; one aged 19 years old gave assent but caregiver consent 
was obtained on the basis of a self-reported age of 16 years at screening]). §Four patients assigned no-RUSF and 
two assigned RUSF were not formally lost to follow-up (they were seen in the clinic within 91 days of week 48). 
¶Time-to-event analyses included all times at-risk from randomisation to the earliest of the event or last clinical 
follow-up if the event had not occurred (details on adherence to randomised strategy in appendix).
2356 screened
1805 randomly assigned‡
551* not randomly assigned
           Protocol exclusion criteria
384 screening CD4 count 
≥100 cells per μL 
28 blood test contraindications
20 ART experienced
29 did not consent
11 other contraindications
8 pregnancy or breastfeeding
5 received single-dose nevirapine
Other reasons
35 died before enrolment
28 did not return in screening window
24 starting ART from different source
4 moved
3 other†
873 (97%) initiated RUSF 
24 (3%) initiated RUTF
2 (<1%) started RUSF 1–2 weeks 
post randomisation
41 (5%) discontinued RUSF 
permanently before 12 weeks
5 (<1%) received >14 weeks of RUSF 
in error
897 assigned to RUSF908 assigned to no-RUSF
908 included in intention-to-treat analysis¶
132 discontinued the trial
19 lost to follow-up
11 withdrew consent§
111 died
897 included in intention-to-treat analysis¶
1 (<1%) initiated RUSF
38 (4%) initiated RUTF
141 discontinued the trial 
23 lost to follow-up 
9 withdrew consent§
114 died
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Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding authors had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication.
Results
Between June 18, 2013, and April 10, 2015, we randomly 
assigned 1805 participants to treatment, 897 to RUSF and 
908 to no-RUSF (figure 1), who were included in the 
analyses. 28 participants (3%) from each group were lost 
to follow-up (p=1·00). 104 (12%) assigned RUSF versus 
108 (12%) no-RUSF missed at least one scheduled visit 
before death or loss to follow-up (p=0·84). Baseline 
characteristics were well balanced between groups (table, 
appendix p 6).
All participants assigned RUSF started either RUSF or 
RUTF; one (<1%) individual assigned no-RUSF started 
RUSF in error (table, figure 1). Of 111 no-RUSF 
participants with BMI less than 16 kg/m², 27 (24%) were 
prescribed RUTF (appendix p 7). In the first 12 weeks on 
ART, the RUSF group spent 95% person-time prescribed 
RUSF and 2% person-time prescribed RUTF versus 2% 
and 3% respectively in the no-RUSF group (appendix p 19). 
After 12 weeks, 2% and <1% person-time was spent 
prescribed RUSF and RUTF, respectively, in the RUSF 
group, and 1% and <1% person-time, respectively, in the 
no-RUSF group. 207 participants (27%) of 769 in the 
RUSF group reported missing any RUSF at weeks 0–4 
and 129 (19%) of 685 at weeks 8–12 (appendix p 20). 
110 participants (14%) of 795 in the RUSF group reported 
difficulty taking RUSF every day as prescribed at 4 weeks, 
and 59 (8%) of 734 reported difficulty at 12 weeks 
(appendix p 20).
By 24 weeks, 96 participants (Kaplan-Meier percentage 
10·9%, 95% CI 9·0–13·1) allocated to RUSF and 
92 (10·3%, 8·5–12·5) to no-RUSF died (figure 2, hazard 
ratio [HR] 1·05, 95% CI 0·79–1·40; log-rank p=0·75). By 
48 weeks 111 (12·6%, 10·6–15·0) and 114 (12·8%, 
10·8–15·2) died (0·98, 0·75–1·27; p=0·87). By 12 weeks 
(exploratory analysis), 73 (8·2%) and 74 (8·2%) died (0·99, 
0·72–1·37; p=0·96). There was no evidence of interaction 
with other factorial randomisations (p>0·7). Causes of 
death were similar between the two groups (pexact=0·75; 
appendix p 7). There was some evidence that RUSF could 
be harmful in participants in one of the two Kenyan 
centres (pinteraction=0·02), but no evidence (p>0·1) that 
mortality differences varied across eight other preplanned 
or seven other exploratory subgroups (total 15 analyses; 
one p value <0·05 expected by chance; appendix p 22). In 
particular, there was no evidence that the effect of RUSF 
varied by BMI at ART initiation (p=0·47, 0·45, and 0·50 
using continuous, categorical [of threshold 20 kg/m²], or 
categorical [of threshold 18·5kg/m²] interactions) or by 
reported household food insecurity (p=0·51) or food crop 
growth (p=0·20; appendix p 22).
There was no evidence of an effect of RUSF on disease 
progression (new WHO stage 4 or death p=0·99, new 
WHO stage 3 or 4 or death p=0·86), new tuberculosis 
disease (p=0·91), cryptococcal disease (p=0·96), 
candidiasis (p=0·83), or presumptive severe bacterial 
infections (p=0·45; appendix p 8). There was also no 
evidence for differences in time to first serious adverse 
events, which occurred in 205 participants (23%) 
assigned RUSF and 205 (23%) assigned no-RUSF 
(p=0·81; appendix pp 8–17). The most common type of 
No-RUSF (n=908) RUSF (n=897) All (n=1805)
Male sex 487 (54%) 474 (53%) 961 (53%)
Age at last birthday (years) 36 (29–42; 5–71) 36 (29–42; 6–77) 36 (29–42; 5–77)
5–12 23 (3%) 17 (2%) 40 (2%)
13–17 18 (2%) 14 (2%) 32 (2%)
WHO HIV stage
1 152 (17%) 148 (16%) 300 (17%)
2 293 (32%) 261 (29%) 554 (31%)
3 338 (37%) 353 (39%) 691 (38%)
4 125 (14%) 135 (15%) 260 (14%)
In individuals aged ≥13 years
Weight* (kg)† (n=1760) 52·7 (46·0–59·5) 52·4 (46·5–59·2) 52·5 (46·3–59·3)
BMI* (kg/m2)† (n=1758) 19·3 (17·3–21·6) 19·2 (17·4–21·4) 19·3 (17·4–21·5)
BMI <18·5 kg/m2 354/880 (40·2%) 343/878 (39%) 697/1758 (40%)
MUAC* (cm; n=1764) 24·0 (21·8–26·2) 24·0 (22·0–26·0) 24·0 (22·0–26·1)
Lean body mass (kg; 
n=1704)
41·4 (37·4–46·9) 41·5 (37·2–47·1) 41·5 (37·3–47·0)
Fat mass (kg; n=1707) 6·4 (3·5–12·3) 6·8 (3·8–12·3) 6·6 (3·7–12·3)
Basal metabolic rate 
(kcal/day; n=1674)
1305 (1193–1438) 1300 (1192–1446) 1303 (1192–1441)
Grip strength (k; n=1772) 24·2 (19·2–30·9) 24·7 (19·4–31·1) 24·5 (19·3–31·0)
Household food reported 
sufficient to feed
627/898 (70%) 610/890 (69%) 1237/1788 (69%)
Household reported to grow 
own crops
489/897 (55%) 475/888 (53%) 964/1785 (54%)
CD4 count* (cells per µL) 34 (16–60) 38 (16–64) 37 (16–63)
0–24 344 (38%) 312 (35%) 656 (36%)
25–49 258 (28%) 251 (28%) 509 (28%)
HIV viral load (copies per mL; 
n=1804)
244 110 
(94 550–589 300)
251 680 
(95 680–626 610)
249 770 
(95 280–606 360)
≥100 000 675/908 (74%) 659/896 (74%) 1334/1804 (74%)
<1000‡ 8/908 (<1%) 6/896 (<1%) 14/1804 (<1%)
Haemoglobin (g/L; n=1800) 111 (96–126) 112 (95–128) 112 (96–127)
Supplementation prescribed at randomisation
RUSF§ 1 (<1%) 873 (97%) 874 (48%)
RUTF 38 (4%) 24 (3%) 62 (3%)
No supplementation 869 (96%) 0 869 (48%)
Data are n (%), median (IQR; range), or median (IQR). RUSF=ready-to-use supplementary food. BMI=body-mass index. 
MUAC=mid-upper-arm-circumference. RUTF=ready-to-use therapeutic food. *Mean of screening and enrolment 
values. For eligibility, screening CD4 count had to be <100 cells per µL, so baseline values might be more than 100 cells 
per µL depending on the count at enrolment. †Among children aged younger than 13 years, median (IQR)  
weight-for-age, height-for-age, and BMI-for-age Z scores were –2·6 (–3·4 to –1·5), –1·9 (–2·6 to –1·3), and –1·9 
(–2·8 to –1·1), respectively. ‡Potentially indicating undisclosed previous antiretroviral therapy: median CD4 cell count 
of 76 cells per µL in these participants. §One participant with BMI 17·8 kg/m2 randomly assigned to no-RUSF started 
RUSF on day 0 (protocol deviation). 
Table: Baseline characteristics of the intention-to-treat population
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serious adverse event was specific infections, occurring 
in 90 (10%) of 897 participants assigned RUSF and 
87 (10%) of 908 assigned no-RUSF. There was also no 
evidence of differences in grade 4 adverse events that 
occurred in 181 (20%) and 172 (19%; p=0·45), new 
admissions to hospital that occurred in 169 (19%) and 171 
(19%; p=0·99), or adverse events of grade 3 or 4 that 
occurred in 327 (36%) and 331 (36%; p=0·90; 
appendix p 8). Total number of days admitted to hospital 
were 2342 with no-RUSF versus 2710 with RUSF (rank-
sum p=0·66), from 209 versus 222 admissions, 
respectively (Poisson p=0·44). Adverse events were 
reported as the reason for stopping RUSF (permanently 
or temporarily, regardless of duration) in 46 participants 
(5%; appendix p 18), mainly gastrointestinal events.
Self-reported ART adherence did not differ between 
randomised groups (global p=0·81, appendix p 21). 
Consistent with this finding, there were no differences at 
any timepoint between randomised groups in suppression 
of viral load to fewer than 50 copies per mL (global 
p=0·58, appendix p 23) or change in CD4 cell count 
(p=0·34, appendix p 23). 48 weeks after ART initiation, 
603 participants (81%) of 749 assigned RUSF versus 
599 (79%) of 754 assigned to no-RUSF had a viral load of 
fewer than 50 copies per mL (p=0·61), and the mean 
increases in CD4 count were 154 cells per µL (SD 4·3) and 
155 cells per µL (4·5), respectively (p=0·87; appendix p 23).
Participants aged at least 13 years who were assigned 
RUSF had significantly greater gains in weight, BMI, and 
MUAC through 48 weeks than those assigned no-RUSF 
(overall p=0·004, 0·004, and 0·03, respectively; figure 3). 
Differences between randomised groups were greatest at 
12 weeks (figure 3). There was no evidence that the greater 
anthropometric increases in the RUSF group varied 
according to BMI at ART initiation (appendix p 24). In 
adults and adolescents, estimates from bioimpedance 
analysis suggested that at 12 weeks, in those receiving 
RUSF, the additional weight gain over the no-RUSF 
group comprised of both fat mass (p<0·0001) and fat-free 
mass (p=0·005; figure 4).
Among Zimbabwean adults and adolescent 
participants, waist-circumference, hip-circumference, 
suprailiac skinfold thickness, and the sum-of-four 
skinfold thicknesses (triceps, subscapular, suprailiac, 
and mid-thigh) increased significantly more in those 
assigned RUSF than in those assigned no-RUSF at 
12 weeks (p<0·04, appendix pp 25–28), but differences in 
triceps, subscapular, and mid-thigh skinfold thicknesses 
were not significant (p=0·14–0·21). We observed no 
evidence of sustained differences between randomised 
groups through 48 weeks (global p>0·10). In 
40 participants younger than 13 years, there were no 
differences in the changes in weight-for-age or BMI-for-
age Z scores between groups (appendix p 29).
In all participants, grip strength increased after starting 
ART but changes in grip strength did not differ between 
groups (p=0·36; figure 3), with increases at 12 weeks of 
2·2 kg (SD 0·2) in RUSF versus 2·6 kg (0·2) in no-RUSF 
(p=0·17). There were also no significant differences 
between randomised groups for changes in haemoglobin 
(p=0·88).
Discussion
Among severely immunocompromised individuals 
initiating ART in Africa, universal provision of RUSF did 
not reduce early mortality or change suppression of viral 
load, CD4 cell count recovery, ART adherence, serious 
morbidity events, or recovery of grip strength compared 
with following current guidelines for selective nutritional 
supplementation in severely malnourished patients 
(received by around 4% of the no-RUSF group). Universal 
RUSF was associated with increased gains in weight, 
BMI, and MUAC during the supplementation period 
that were not sustained afterwards. The large size of the 
REALITY trial, and similar mortality risks between the 
RUSF and non-RUSF groups, does not suggest that the 
null result was because of an absence of statistical power. 
In fact, 24-week mortality was higher than anticipated 
(10·5% rather than 7%), meaning that the trial had 80% 
power to detect reductions from 10·5% to 6·5% (HR 0·6). 
There was no evidence of effect modification by baseline 
BMI or self-reported household food insecurity.
Few randomised trials of nutritional supplementation 
in HIV-infected individuals have been designed to assess a 
primary endpoint of mortality or have included an 
unsupplemented control group, aside from treatment of 
severe malnutrition. Instead, nutritional supplementation 
is commonly assumed to be beneficial, probably because 
in observational studies, weight gain among malnourished 
individuals after starting ART has been associated with 
better outcomes.22 However, besides the substantial cost 
implications of lipid-based nutritional supplements, 
Figure 2: Overall mortality through 48 weeks
Dotted vertical line at week 24 when the primary outcome (mortality) was measured. HR=hazard ratio. 
RUSF=ready-to-use supplementary food.
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Figure 3: Changes in weight, BMI, MUAC, and grip strength hrough 48 weeks
Data are mean (95% CI). Figure shows changes in (A) weight, (B) body-mass index (BMI), (C) MUAC (mid-upper-arm-circumference), and (D) grip strength. p values 
compare changes from baseline across randomised groups, and hence adjust for any imbalances at baseline. Weight, BMI, and MUAC were analysed only in those 
aged ≥13 years at initiation of antiretroviral therapy. RUSF=ready-to-use supplementary food. 
Figure 4: Changes in body composition through 48 weeks
Data are mean (95% CI) for patients aged ≥13 years at initiation of antiretroviral therapy. Figure shows changes in (A) fat mass and (B) fat-free mass. p values compare 
changes from baseline across randomly assigned groups and hence adjust for any imbalances at baseline. RUSF=ready-to-use supplementary food.
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individuals starting ART are at risk of metabolic 
abnormalities including insulin resistance and 
dyslipidaemia,23 and there is increasing concern over the 
long-term effects in other contexts where rapid weight 
gain is achieved through lipid-based nutritional 
supplements.
Two trials of nutritional supplementation among 
malnourished individuals starting ART have reported 
mortality endpoints.15,16 The NUSTART trial15 in Tanzania 
and Zambia enrolled 1876 adults with BMI less than 
18·5 kg/m² eligible for ART with CD4 counts fewer 
than 350 cells per µL or stage 3 or 4 HIV disease. 
Participants were randomised to receive a lipid-based 
nutritional supplement with or without additional 
vitamins and minerals (150 kcal per day for 2 weeks, 
then 1400 kcal per day) from referral for ART until 
6 weeks after starting ART. Participants were more 
malnourished than in our trial (mean BMI 16·4 kg/m²), 
although their mean CD4 cell count was higher (around 
135 cells per µL). 365 participants (19%) died 12 weeks 
after starting ART, with no differences in mortality 
between randomised groups (rate ratio 0·99, 95% CI 
0·80–1·21), and no differences in changes in BMI or 
incidence of serious adverse events. Those allocated 
RUSF with micronutrients had a modestly greater 
increase in CD4 cell count. In the second trial,16 
491 Malawian adult men with BMI less than 18·5 kg/m² 
were randomly assigned at ART initiation to receive 
either RUSF or a blend of corn and soy, both providing 
1360 kcal per day. Mean baseline BMI and CD4 counts 
were similar to those in the NUSTART trial: 16·5 kg/m² 
and 131–142 cells per µL). Participants allocated RUSF 
gained more BMI and lean mass than those allocated 
the blend of corn and soy, but there was no difference 
between groups at study end in participants categorised 
as moderately or severely malnourished. Mortality to 
14 weeks was similar in the two groups (26% and 27%). 
At 12 months, both groups had similar BMI, fat-free 
body mass, number of admissions to hospital, and 
mortality.
Another trial (ARTFood)17 in Ethiopia included an 
unsupplemented control group, but was not designed to 
assess mortality. In this study, 282 adults initiating ART 
with BMI greater than 17 kg/m² were randomly assigned 
either early supplementation with immediate whey-
based or soy-based RUSF (1100 kcal per day for 3 months), 
or delayed supplementation, 3 months after ART 
initiation. The median baseline BMI (19·8–20·0 kg/m²) 
was similar to that in our trial, but the median CD4 
counts were higher (181–191 cells per µL). Early RUSF 
supplementation was associated with gains in weight 
and lean mass (+2·1 kg total, +0·9 kg lean body-mass; 
BMI changes not reported) and a small increase in grip 
strength. There were no differences in viral load or CD4 
cell counts and only four participants were reported to 
have died. At 12 months, there was no difference in 
weight gain between groups.
Compared with the ARTFood trial, in REALITY 
we enrolled only profoundly immunocompromised 
individuals at much higher risk of mortality. The 
differential short-term weight gain with RUSF (+0·9 kg 
total; +0·4 kg fat-free mass) was somewhat smaller than 
that noted in the ARTFood trial. We also showed, unlike 
in ARTFood, that grip strength improved irrespective of 
allocation to RUSF. These two findings probably reflect 
differences between the participants in the ARTFood and 
REALITY trials. Any wasting and weakness in our trial 
might have been more because of the effects of HIV (as 
indicated by their severely immunocompromised status) 
than primary undernutrition,22 with corresponding 
differences in the metabolic responses to ART and 
nutritional supplementation. Additionally, although only 
40% of participants in our trial had BMI less than 
18·5 kg/m², we noted no evidence that the effect of RUSF 
varied by BMI at baseline, whether this was considered 
as a continuous factor, or when stratified by common 
thresholds to define malnutrition or undernutrition (ie, 
18·5 or 20·0 kg/m²).
In 2015, a systematic review14 of nutritional assessment, 
counselling, and support in people living with HIV did 
not identify any further trials with a mortality endpoint. 
The review concluded that studies were of variable and 
largely poor quality and the effect of nutritional 
supplementation on mortality, morbidity, and disease 
outcomes was uncertain.14 In 2013, a Cochrane review13 
identified 11 trials including a total of 1725 HIV-infected 
adults with different disease stages, ART status, and 
nutritional status, comparing various supplements with 
placebo, no supplementation, nutrition counselling 
alone, or usual diet. No trials were identified assessing 
the effect of macronutrient interventions on mortality as 
a primary outcome. Meta-analysis showed a significant 
effect of supplementation on increasing energy and 
protein intake, but no evidence of efficacy of nutritional 
supplementation on clinical, anthropometric, or 
immunological outcomes.13
The major strengths of our trial were its large size, the 
mortality primary endpoint in a well defined, high-risk 
population, and having a non-supplemented comparison 
group aside from a small proportion who were severely 
malnourished. For generalisability, we included a large 
number of participants at eight HIV clinics across four 
African countries. Our limitations included that the 
results cannot inform on the potential effect of RUSF 
provision on retention in clinic follow-up in a real-world 
setting since the design included defaulter tracing 
because this was a clinical trial. Other limitations 
included the absence of precise data on actual home use 
or sharing of RUSF, and on feeding frequency and 
dietary diversity. We also recruited fewer children than 
planned, limiting our ability to assess effects in this 
subgroup; we planned to enrol 300 children older than 
5 years but found few children with CD4 cell counts less 
than 100 cells per µL, potentially as a result of increasing 
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coverage of ART to prevent mother-to-child HIV 
transmission. By contrast, we recruited adults much 
faster than expected, suggesting trial results are 
generalisable to the population presenting with low CD4 
cell counts.
Consistent with results from previous trials, those from 
our REALITY trial showed that increasing weight gain by 
universal lipid-based supplementation, which occurred 
across all baseline BMI subgroups, did not lead to 
reductions in mortality. This finding suggests that there is 
not a direct causal relation between BMI and mortality. 
Instead, the main drivers of mortality seem to be 
opportunistic infections as a result of immuno- 
suppression and systemic immune activation,24 which, 
together with reduced appetite and feeding or swallowing 
difficulties, lead to low BMI, and might not be directly 
improved by nutritional rehabilitation.25 Besides reducing 
viral load and preventing opportunistic infections, new 
strategies to reduce immune activation might improve 
outcomes.25,26 Systemic inflammation in HIV particularly 
arises from the gastrointestinal tract,26,27 thus interventions 
targeting gut dysfunction, inflammation, microbial 
translocation, and the microbiota are promising targets 
for further research.28
Both undernutrition and nutritional supplementation 
have been reported to change the pharmacokinetics of 
ART. In one study of Ugandan women,29 exposure to 
lopinavir, ritonavir, and efavirenz was lower in those who 
were undernourished, ascribed to decreased bioavailability. 
Fat might increase efavirenz absorption; however, in 
another study of Ethiopian adults,30 allocation to lipid-
based nutritional supplementation did not affect efavirenz 
plasma concentrations, although plasma nevirapine 
concentrations were lower. In our trial, ART regimens 
were well balanced across the groups (appendix p 6) and 
we showed no evidence of differences in viral load 
suppression, thus there was no suggestion of clinically 
significant changes in the bioavailability of antiretroviral 
drugs with RUSF.
Among severely immunocompromised adults and older 
children initiating ART, the REALITY trial provides evidence 
that universally providing lipid-based RUSF increases 
bodyweight in the short-term, but does not improve 
mortality, disease progression, viral load, or immunological 
recovery compared with selectively prescribing RUSF or 
RUTF to severely malnourished individuals according to 
current protocols. Although individuals with severe 
malnutrition should continue to be identified and treated, a 
change in policy to provide lipid-based nutritional 
supplements to all severely immunocompromised 
individuals starting ART is not warranted.
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